Framework for Future Studies of Convalescent Plasma for COVID-19 and New Infectious Diseases

Strategic Insights -

Researchers from the Albert Einstein College of Medicine and Montefiore Medical Center propose a framework for future studies of convalescent plasma (CP) for COVID-19 and new infectious diseases. The use of CP, which is rich in specific antibodies that can neutralize viruses, has shown promise in treating COVID-19 patients, particularly those who are immunocompromised or treated early in the disease. However, previous studies have been inconsistent, with some demonstrating no overall efficacy. The proposed framework aims to design clinical studies that adhere to the principles of antibody therapy, including obtaining high-quality CP and administering it during the viral phase of the disease, to generate a robust evidence base for using CP.

Key Takeaways:

  • Researchers propose a framework for future studies of convalescent plasma (CP) for COVID-19 and new infectious diseases, focusing on designing clinical studies that adhere to the principles of antibody therapy.
  • The proposed framework includes obtaining high-quality CP and administering it during the viral phase of the disease in immunocompromised or very early in immunocompetent individuals.
  • Previous studies have shown inconsistent results, with some demonstrating no overall efficacy of CP in treating COVID-19 patients despite signals of benefit in certain subgroups.
  • The proposed framework aims to generate a robust evidence base for using CP, which is rich in specific antibodies that can neutralize viruses.
  • CP has shown promise in treating COVID-19 patients, particularly those who are immunocompromised or treated early in the disease.
  • The research was conducted by investigators at the Albert Einstein College of Medicine and Montefiore Medical Center.

Statistics:

  • 2019: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept across the world and emerged as the cause of the coronavirus disease 19 (COVID-19) pandemic in early 2020.
  • Early 2020: The use of convalescent plasma (CP) was rapidly deployed for COVID-19 patients with no validated treatments or prior immunity existed.
  • 2025: Research proposed a framework for future studies of CP for COVID-19 and new infectious diseases, focusing on designing clinical studies that adhere to the principles of antibody therapy.
  • The framework aims to generate a robust evidence base for using CP, which is rich in specific antibodies that can neutralize viruses.

Sources:

  • Generating the Evidence Base for Convalescent Plasma Use for a New Infectious Disease. Current Topics in Microbiology and Immunology, 2025;443:205-217.
  • Springer International Publishing Ag. Current Topics in Microbiology and Immunology can be contacted at: Gewerbestrasse 11, Cham, Ch-6330, Switzerland.
  • NewsRx. Findings from Albert Einstein College of Medicine and Montefiore Medical Center in the Area of COVID-19 Reported (Generating the Evidence Base for Convalescent Plasma Use for a New Infectious Disease). Drug Week. October 31, 2025; p 27.